UK leads Europe in new AMD therapy
Ophthalmologists in the UK are leading adopters of a new treatment for age-related macular degeneration (AMD), it was announced yesterday (May 19) at the Royal College of Ophthalmologists Annual Congress, in Liverpool.
Oraya Therapy delivers targeted, low-energy X-rays to the damaged retinas of patients with wet AMD. The non-invasive treatment is intended as a single outpatient procedure, with clinical data showing it may reduce the required number of anti-VEGF injections needed to treat the disease.
Since its introduction to the UK two years ago, the treatment is now available at four centres in the Uk, based in Sheffield, Manchester, the West Midlands and Kent. One hospital trust in particular, Sheffield Teaching Hospitals NHS Foundation Trust, has treated more than 150 AMD patients using Oraya Therapy.
“We need additional therapies to anti-VEGF injections in treating wet AMD,” said Christopher Brand, a consultant ophthalmologist at Royal Hallamshire Hospital in Sheffield. The consultant added: “In addition to benefiting patients, Oraya Therapy can reduce the burden of care in our clinics and hospitals as the number of wet AMD patients increases.”
President and CEO of Oraya Therapeutics, Jim Taylor, said: “Over the past two years, we’ve had the honour of collaborating with many UK ophthalmologists who are working diligently and with good effect to treat wet AMD patients. We are pleased to see the integration of Oraya Therapy into standard clinical care, and look forward to establishing additional treatment centres in the coming months.”
Oraya Therapy is also available in Austria, Czech Republic, Germany and Italy.